At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 10 enrolled
Drug / intervention
Neratinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study Of Neratinib (HKI-272) In Combination With Paclitaxel In Subjects With Solid Tumors
In Brief
A Phase 1 clinical trial evaluating Neratinib and Paclitaxel for Advanced Malignant Solid Tumors. Completed, enrolled 10 participants across 2 sites.
Detailed Summary
This is an open-label, phase 1 study of ascending multiple oral doses of HKI-272 in combination with paclitaxel.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Solid Tumors
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedOct 2008
Primary CompletionJan 2011
TodayJul 2026
First PostedOct 8, 2008
Enrollment StartOct 1, 2008
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.7 years ago
Interventions
Neratinibdrug
Administered orally, continuous, once daily.
Paclitaxeldrug
Administered IV, on days 1, 8, 15 of 28 day cycle.